Healio

Evinacumab shows benefit in certain patients with severe hypertriglyceridemia

Please provide your email address to receive an email when new articles are posted on . The reductions after treatment with evinacumab (Evkeeza, Regeneron) were evident in certain patients from two ...
Monthly Prescribing Reference

Olezarsen Cuts Triglyceride Levels in Patients With Familial Chylomicronemia Syndrome

Credit: Getty Images. In FCS, mutations in the lipoprotein lipase gene lead to an accumulation of chylomicrons in plasma resulting in severe hypertriglyceridemia. Treatment with olezarsen ...
Monthly Prescribing Reference

Tryngolza Approved for Familial Chylomicronemia Syndrome

Credit: Ionis Tryngolza is an apoC-III-directed antisense oligonucleotide that is administered subcutaneously once monthly. As an adjunct to a low fat diet, Tryngolza significantly reduced fasting ...
Healio

Olezarsen may not prevent coronary plaque progression, despite cutting triglycerides

Monthly olezarsen reduced triglycerides and apolipoprotein B in patients with hypertriglyceridemia but may have no impact on ...
FiercePharma

ACC 2021: Regeneron's Evkeeza aces triglyceride control, but only in certain patients

Regeneron’s new med Evkeeza already sports an approval in the ultra-rare disease homozygous familial hypercholesterolemia, which is associated with extreme levels of cholesterol. But thanks to ...
Nasdaq

TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet

CARLSBAD, Calif., Dec. 19, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZA™ (olezarsen) as an ...
WebMD

What Is Familial Hyperchylomicronemia Syndrome?

Familial hyperchylomicronemia syndrome (FCS) is a rare disorder you get from genes passed down from your parents. When you have it, your body isn’t able to break down (metabolize) fat. Specifically, ...
MedPage Today

Antisense Drug Slashes High Triglycerides

ATLANTA -- A novel antisense mRNA drug slashed triglycerides in higher risk or moderate hypertriglyceridemia patients and in those with extremely elevated levels from familial chylomicronemia syndrome ...
Seeking Alpha

TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)

– Recommendation based on Phase 3 Balance results, which showed a significant reduction of triglycerides and substantial reduction of acute pancreatitis events with TRYNGOLZA – – European Commission ...
Nasdaq

Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China

PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the Chinese National Medical Products Administration (NMPA) has approved REDEMPLO® (plozasiran) ...
Seeking Alpha

Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome

CARLSBAD, Calif., Feb. 15, 2024 /PRNewswire/ -- Ionis Pharmaceuticals (IONS), Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation ...